Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00520-021-06523-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TRAF1 improves cisplatin-induced acute kidney injury via inhibition of inflammation and metabolic disorders.
Biochim Biophys Acta Gen Subj
September 2023
Nanjing Key Lab of Pediatrics, Children's Hospital of Nanjing Medical University, Nanjing 210008, China; Jiangsu Key Laboratory of Pediatrics, Nanjing Medical University, Nanjing 210029, China; Department of Nephrology, State Key Laboratory of Reproductive Medicine, Children's Hospital of Nanjing Me
Background: Cisplatin-induced acute kidney injury (AKI) is a severe clinical complication with no satisfactory therapies in the clinic. Tumor necrosis factor receptor (TNFR)-associated factor 1 (TRAF1) plays a vital role in both inflammation and metabolism. However, the TRAF1 effect in cisplatin induced AKI needs to be evaluated.
View Article and Find Full Text PDFCorrection to: Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
Support Care Cancer
November 2021
Mayo Clinic, Rochester, MN, USA.
The flavonoid 6-hydroxyflavone prevention of cisplatin-induced nephrotoxicity.
Histol Histopathol
October 2020
Department of Prosthetic Dental Science, College of Dentistry, King Saud University, Riyadh, Saudi Arabia.
In this study, the flavonoid, 6-hydroxyflavone was investigated for its renal protective activity in the cisplatin rat model of nephrotoxicity. Male Sprague-Dawley rats weighing 200-250 g were included in the study. 6-Hydroxyflavone was daily administered at 25 and 50 mg/kg (i.
View Article and Find Full Text PDFAcute stroke secondary to carotid artery dissection in a patient with germ cell tumour: did cisplatin play a role?
Onkologie
August 2013
Department of Neurosciences, University Hospitals Coventry and Warwickshire, United Kingdom.
Background: Cisplatin-based chemotherapy - mainly the bleomycin, etoposide and cisplatin (BEP) regimen - has significantly improved the prognosis of testicular germ cell tumours (GCT). However, it has serious vascular side effects, including acute ischemic stroke.
Case Report: A 37-year-old man with no conventional cerebrovascular risk factors presented with right arm clumsiness followed by a transient episode of expressive dysphasia 3 h later.
Recombinant human erythropoietin treatment in elderly cancer patients with cisplatin-associated anemia.
Oncology
September 1995
Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italia.
The efficacy of recombinant human erythropoietin (rHuEPO) on the increase in hemoglobin levels was assessed in patients with cisplatin (CDDP)-induced anemia older than 70 years. Furthermore, we compared the results obtained in this group of patients with those observed in other patients receiving rHuEPO for a CDDP-associated anemia with similar clinical features (chemotherapeutic regimen, primary tumor; CDDP cumulative dose) but of an age less than 70 years. Twenty patients older than 70 years with a CDDP-associated anemia (hemoglobin levels < 90 milligrams) received rHuEPO at the dose of 100 U/kg subcutaneously, three times a week.
View Article and Find Full Text PDF